<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A new scale for motor function measurement has been developed for <z:e sem="disease" ids="C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The validation study included 303 patients, aged 6-62 years </plain></SENT>
<SENT sid="2" pm="."><plain>Seventy-two patients had Duchenne <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo>, 32 Becker <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo>, 30 <z:hpo ids='HP_0006785'>limb-girdle muscular dystrophy</z:hpo>, 39 facio-scapulo-humeral <z:mpath ids='MPATH_554'>dystrophy</z:mpath>, 29 myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath>, 21 congenital <z:hpo ids='HP_0003198'>myopathy</z:hpo>, 10 <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo>, 35 <z:hpo ids='HP_0007269'>spinal muscular atrophy</z:hpo> and 35 hereditary <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The scale comprised 32 items, in three dimensions: standing position and transfers, axial and proximal motor function, distal motor function </plain></SENT>
<SENT sid="4" pm="."><plain>Agreement coefficients for inter-rater reliability were excellent (kappa=0.81-0.94) for nine items, good (kappa=0.61-0.80) for 20 items and moderate (kappa=0.51-0.60) for three items </plain></SENT>
<SENT sid="5" pm="."><plain>High correlations were found between the total score and other scores: Vignos (r=0.91) and Brooke (r=0.85) grades, Functional Independence Measure (r=0.91), the global severity of disability evaluated with visual analog scales by physicians (r=0.88) and physiotherapists (r=0.91) </plain></SENT>
<SENT sid="6" pm="."><plain>This scale is reliable, does not require any special equipment and is well-accepted by patients </plain></SENT>
<SENT sid="7" pm="."><plain>Its sensitivity to change is being assessed to permit its use in clinical trials of <z:e sem="disease" ids="C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular diseases</z:e> </plain></SENT>
</text></document>